Document registry — page 15
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Consultation on the draft of CEI-MS-07, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
21 Jul 2026 -
Oral non-peptide GLP-1 receptor agonist. Small-molecule GLP-1 receptor agonism with a short half-life requiring twice-daily administration. The Institute includes this monograph specifically…
Low20 Jul 2026 -
Peptides, SARMs, injectable oils and raw materials. 350+ catalogue lines.
20 Jul 2026 -
Consultation on the draft of this analytical evidence review, which registers the question: How much does a reported chromatographic purity figure vary with the method…
19 Jul 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low19 Jul 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the…
Moderate18 Jul 2026 -
Consultation on the draft monograph for MOTS-c, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
15 Jul 2026 -
Amylin analogue, short-acting. Pramlintide reproduces the postprandial actions of endogenous amylin, which is deficient in insulin-deficient diabetes: it slows gastric emptying…
Moderate15 Jul 2026 -
Thymic peptide extract of undefined composition. Thymalin is a fractionated calf-thymus extract registered in the Russian Federation as an immunomodulator. Because its composition is not defined, no…
Very low15 Jul 2026 -
Consultation on the draft of this intervention review, which registers the question: What randomised evidence supports mitochondria-targeted peptides in primary…
14 Jul 2026 -
Consultation on the draft synthesis of incretin receptor agonists for metabolic dysfunction-associated steatohepatitis. The anchor outcome is histological, which raises…
12 Jul 2026 -
Event-driven cardiovascular outcome trial, phase 3 study of Survodutide in cardiovascular and obesity over event-driven. The Institute holds no reported primary result…
11 Jul 2026 -
Consultation on the draft certainty index, a cross-cutting finding aid that lists every assessed outcome in the document set by its certainty rating. The index makes it…
10 Jul 2026 -
Consultation on the draft monograph for orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist. The draft assesses a compound whose phase 3 programme…
06 Jul 2026 -
Consultation on the draft monograph for SS-31 (elamipretide), which the assessment committee released for public comment before ratification. The draft grades the…
04 Jul 2026 -
Consultation on the draft of CEI-MS-13, which specifies the performance a determination must achieve for method validation and states what the resulting figure does not…
04 Jul 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide compared with the comparator…
High04 Jul 2026 -
Consultation on the draft monograph for Sermorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
03 Jul 2026 -
What randomised human evidence exists for BPC-157 in any indication?
Very low03 Jul 2026 -
Consultation on the draft monograph for KPV, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
02 Jul 2026 -
Consultation on the draft monograph for Pramlintide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
30 Jun 2026 -
Consultation on the draft monograph for PT-141 (bremelanotide), which the assessment committee released for public comment before ratification. The draft grades the…
30 Jun 2026 -
Consultation on the draft standard for freeze–thaw and in-use stability assessment of reconstituted peptide solutions. The draft specifies the cycling regime, the hold…
26 Jun 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over 76 weeks. The Institute holds no reported primary result…
26 Jun 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, is the effect of Exenatide maintained across the full duration of…
High25 Jun 2026 -
Record of documents ratified in the 2026 Q2 assessment cycle.
22 Jun 2026 -
Dual glucagon and GLP-1 receptor agonist (oxyntomodulin analogue). Mazdutide reproduces the natural dual activity of oxyntomodulin with a pharmacokinetic profile suitable for weekly dosing. The glucagon arm…
Moderate22 Jun 2026 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High18 Jun 2026 -
Freeze–thaw and in-use stability assessment of reconstituted peptide solutions
High16 Jun 2026 -
Growth-hormone-releasing hormone fragment analogue. Sermorelin stimulates pituitary growth-hormone release through the GHRH receptor. Its very short half-life confines the pharmacodynamic effect to a…
Low15 Jun 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low15 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its comparator?
Moderate12 Jun 2026 -
Peptides, SARMs, injectable oils and raw materials. Long-established synthesis operation.
12 Jun 2026 -
In the population defined for cutaneous wound healing and tissue repair, what is the effect of Thymosin beta-4 compared with the comparator used in its contributing…
Low10 Jun 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the effect of Thymosin alpha-1 compared with the comparator used in its…
Moderate09 Jun 2026 -
Peptides and SARMs with a global warehouse network. Trades as Homopeptide.
07 Jun 2026 -
Consultation on the draft monograph for Lixisenatide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
06 Jun 2026 -
Consultation on the draft of CEI-MS-04, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…
05 Jun 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the incidence of adverse events leading to discontinuation with PT-141…
Moderate05 Jun 2026
page 15 of 41